temozolomide has been researched along with Cancer of Ovary in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this report, we present the case of a 3-year-old girl with glioblastoma who continues to experience an exceptional and durable response (>2 years) to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib." | 7.96 | Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. ( Britt, N; Chudnovsky, Y; Duncan, D; Edgerly, C; Elvin, J; Erlich, RL; Gay, L; Gorelyshev, S; Hemmerich, A; Huang, RSP; Konovalov, A; Kram, DE; McCorkle, J; Miller, V; Ramkissoon, SH; Rankin, A; Ross, JS; Savateev, A; Severson, E; Trunin, Y; Valiakhmetova, A, 2020) |
| " In this report, we present the case of a 3-year-old girl with glioblastoma who continues to experience an exceptional and durable response (>2 years) to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib." | 3.96 | Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. ( Britt, N; Chudnovsky, Y; Duncan, D; Edgerly, C; Elvin, J; Erlich, RL; Gay, L; Gorelyshev, S; Hemmerich, A; Huang, RSP; Konovalov, A; Kram, DE; McCorkle, J; Miller, V; Ramkissoon, SH; Rankin, A; Ross, JS; Savateev, A; Severson, E; Trunin, Y; Valiakhmetova, A, 2020) |
| " This paper discusses the early clinical work published showing their use in combination with temozolomide in malignant melanoma, and in familial (BRCA-related) cancers." | 3.74 | PARP inhibitors and cancer therapy - early results and potential applications. ( Jones, C; Plummer, ER, 2008) |
| " The biological effects of two novel PARP inhibitors, NU1025 (8-hydroxy-2-methylquinazolin-4-[3H]one, Ki = 48 nM) and NU1085 [2-(4-hydroxyphenyl)benzamidazole-4-carboxamide, Ki = 6 nM], in combination with temozolomide (TM) or topotecan (TP) have been studied in 12 human tumor cell lines (lung, colon, ovary, and breast cancer)." | 3.70 | Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. ( Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW, 2000) |
| "Temozolomide was administered orally at an initial dose of 150 mg/m(2) daily for 5 days, every 4 weeks." | 2.71 | A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer. ( Argenta, PA; Blair Harkness, C; Boente, MP; Carson, LF; Downs, LS; Judson, PL, 2004) |
| "To improve the treatment of women with ovarian cancer, we are investigating the modulation of a prominent DNA-damaging agent, temozolomide, by manipulating the DNA base excision repair (BER) pathway via BER inhibitor, methoxyamine, and overexpression of N-methylpurine DNA glycosylase (MPG)." | 1.34 | Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. ( Fishel, ML; He, Y; Kelley, MR; Smith, ML, 2007) |
| "Temozolomide is an alkylating agent that mediates its cytotoxic effects via O(6)-methylguanine (O(6)-meG) adducts in DNA." | 1.32 | Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase. ( Barvaux, VA; Gillum, AM; Lorigan, P; Margison, GP; McElhinney, RS; McMurry, TB; Ranson, M, 2004) |
| " To that end, a novel method, based on physiologically based hybrid pharmacokinetic models, is presented to predict human tumor drug concentrations." | 1.32 | Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. ( Bookman, MA; Gallo, JM; Guo, P; Li, S; Ma, J; Orlansky, A; Pulfer, S; Vicini, P; Zhou, F, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, ZC | 1 |
| Li, T | 1 |
| Tully, E | 1 |
| Huang, P | 1 |
| Chen, CN | 1 |
| Oberdoerffer, P | 1 |
| Gaillard, S | 1 |
| Shih, IM | 1 |
| Wang, TL | 1 |
| Valiakhmetova, A | 1 |
| Gorelyshev, S | 1 |
| Konovalov, A | 1 |
| Trunin, Y | 1 |
| Savateev, A | 1 |
| Kram, DE | 1 |
| Severson, E | 1 |
| Hemmerich, A | 1 |
| Edgerly, C | 1 |
| Duncan, D | 1 |
| Britt, N | 1 |
| Huang, RSP | 1 |
| Elvin, J | 1 |
| Miller, V | 1 |
| Ross, JS | 1 |
| Gay, L | 1 |
| McCorkle, J | 1 |
| Rankin, A | 1 |
| Erlich, RL | 1 |
| Chudnovsky, Y | 1 |
| Ramkissoon, SH | 1 |
| Grimm, C | 1 |
| Fischer, A | 1 |
| Farrelly, AM | 1 |
| Kalachand, R | 1 |
| Castiglione, R | 1 |
| Wasserburger, E | 1 |
| Hussong, M | 1 |
| Schultheis, AM | 1 |
| Altmüller, J | 1 |
| Thiele, H | 1 |
| Reinhardt, HC | 1 |
| Hauschulz, K | 1 |
| Hennessy, BT | 1 |
| Herwig, R | 1 |
| Lienhard, M | 1 |
| Buettner, R | 1 |
| Schweiger, MR | 1 |
| Jones, C | 1 |
| Plummer, ER | 1 |
| Judson, PL | 1 |
| Blair Harkness, C | 1 |
| Boente, MP | 1 |
| Downs, LS | 1 |
| Argenta, PA | 1 |
| Carson, LF | 1 |
| Barvaux, VA | 1 |
| Lorigan, P | 1 |
| Ranson, M | 1 |
| Gillum, AM | 1 |
| McElhinney, RS | 1 |
| McMurry, TB | 1 |
| Margison, GP | 1 |
| Gallo, JM | 1 |
| Vicini, P | 1 |
| Orlansky, A | 1 |
| Li, S | 1 |
| Zhou, F | 1 |
| Ma, J | 1 |
| Pulfer, S | 1 |
| Bookman, MA | 1 |
| Guo, P | 1 |
| Paik, J | 1 |
| Duncan, T | 1 |
| Lindahl, T | 1 |
| Sedgwick, B | 1 |
| Fishel, ML | 1 |
| He, Y | 1 |
| Smith, ML | 1 |
| Kelley, MR | 1 |
| Jean-Claude, BJ | 1 |
| Mustafa, A | 1 |
| Damian, Z | 1 |
| De Marte, J | 1 |
| Vasilescu, DE | 1 |
| Yen, R | 1 |
| Chan, TH | 1 |
| Leyland-Jones, B | 1 |
| Delaney, CA | 1 |
| Wang, LZ | 1 |
| Kyle, S | 1 |
| White, AW | 1 |
| Calvert, AH | 1 |
| Curtin, NJ | 1 |
| Durkacz, BW | 1 |
| Hostomsky, Z | 1 |
| Newell, DR | 1 |
| Plumb, JA | 1 |
| Strathdee, G | 1 |
| Sludden, J | 1 |
| Kaye, SB | 1 |
| Brown, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase II Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.[NCT03467178] | Phase 2 | 119 participants (Anticipated) | Interventional | 2018-07-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for temozolomide and Cancer of Ovary
| Article | Year |
|---|---|
A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine | 2004 |
11 other studies available for temozolomide and Cancer of Ovary
| Article | Year |
|---|---|
Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors.
Topics: Animals; Antineoplastic Agents; DNA-Binding Proteins; Epigenesis, Genetic; Female; Humans; Mammals; | 2023 |
Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
Topics: Antineoplastic Agents; Child; Child, Preschool; Female; Glioblastoma; Humans; Neoplasm Recurrence, L | 2020 |
Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing.
Topics: BRCA1 Protein; Cell Line, Tumor; Cell Survival; DNA Methylation; DNA Mutational Analysis; E1A-Associ | 2019 |
PARP inhibitors and cancer therapy - early results and potential applications.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Dacarbazine; En | 2008 |
Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; | 2004 |
Pharmacokinetic model-predicted anticancer drug concentrations in human tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Computer Simu | 2004 |
Sensitization of human carcinoma cells to alkylating agents by small interfering RNA suppression of 3-alkyladenine-DNA glycosylase.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Dacarbazine; DNA Glycosylases; Female; Ge | 2005 |
Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Base Sequence; Cell Line, Tumor; Dacarbazine; DNA Dama | 2007 |
Cytokinetics of a novel 1,2,3-triazene-containing heterocycle, 8-nitro-3-methyl-benzo-1,2,3,5-tetrazepin-4(3H)-one (NIME), in the human epithelial ovarian cancer cell line OVCAR-3.
Topics: Alkylation; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Azepines; Base Sequence; Bindi | 1999 |
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazin | 2000 |
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2000 |